{
    "organizations": [],
    "uuid": "ebd77314c72da4851d10f2316b1e20d6c26c973f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-clearside-biomedical-provides-upda/brief-clearside-biomedical-provides-update-on-two-phase-3-clinical-trials-of-cls-ta-in-retinal-vein-occlusion-idUSASB0C8XY",
    "ord_in_thread": 0,
    "title": "BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Clearside Biomedical Inc:\n* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION\n* CLEARSIDE BIOMEDICAL INC - ‍NOW EXPECTS TO REPORT PRELIMINARY DATA FROM SAPPHIRE TRIAL IN Q4 OF 2018 INSTEAD OF Q1 OF 2019​\n* CLEARSIDE BIOMEDICAL - ‍IF PRIMARY ENDPOINTS MET IN BOTH TOPAZ AND SAPPHIRE TRIALS, CO EXPECTS TO SEEK AGNOSTIC LABEL IN U.S. Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T20:43:00.000+02:00",
    "crawled": "2018-03-07T19:47:49.033+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "clearside",
        "biomedical",
        "inc",
        "clearside",
        "biomedical",
        "provides",
        "update",
        "two",
        "phase",
        "clinical",
        "trial",
        "retinal",
        "vein",
        "occlusion",
        "clearside",
        "biomedical",
        "inc",
        "expects",
        "report",
        "preliminary",
        "data",
        "sapphire",
        "trial",
        "q4",
        "instead",
        "q1",
        "clearside",
        "biomedical",
        "primary",
        "endpoint",
        "met",
        "topaz",
        "sapphire",
        "trial",
        "co",
        "expects",
        "seek",
        "agnostic",
        "label",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}